Eslicarbazepine — Membership Pricing

Other medications in Neurological

• Felbamate
• Fenfluramine
• Fingolimod
• Fosphenytoin
• Fremanezumab
• Galantamine
• Galcanezumab
• Glatiramer

What Eslicarbazepine is approved for (FDA label)

Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. Eslicarbazepine acetate tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 7, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Eslicarbazepine (FDA label)

Eslicarbazepine acetate tablets are available in the following shapes and color (Table 2) with respective two-sided debossing: Table 2: Eslicarbazepine Acetate Tablet Presentations Tablet Strength Tablet Color/Shape Tablet Markings Functional Score 200 mg White to off-white oblong bi-convex ‘E’ on the left side and ‘T’ on the right side of score line on one side and ‘200’ on the other side Yes 400 mg White to off-white round bi-convex ‘ET’ on one side and ‘400’ on the other side No 600 mg White to off-white oblong bi-convex ‘E’ on the left side and ‘T’ on the right side of score line on one side and ‘600’ on the other side Yes 800 mg White to off-white oblong bi-convex ‘E’ on the left side and ‘T’ on the right side of score line on one side and ‘800’ on the other side Yes Tablets: 200 mg, 400 mg, 600 mg, 800 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2067fb77-9657-44da-b430-02e8a4efacb5. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Eslicarbazepine (FDA label)

The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Suicidal Behavior and Ideation [see Warnings and Precautions (5.1) ] Serious Dermatologic Reactions [see Warnings and Precautions (5.2) ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.3) ] Anaphylactic Reactions and Angioedema [see Warnings and Precautions (5.4) ] Hyponatremia [see Warnings and Precautions (5.5) ] Neurological Adverse Reactions [see Warnings and Precautions (5.6) ] Drug Induced Liver Injury [see Warnings and Precautions (5.8) ] Abnormal Thyroid Function Tests [see Warnings and Precautions (5.9) ] Pancytopenia, Agranulocytosis, and Leukopenia [see Warnings and Precautions (5.10) ] Most common adverse reactions in adult patients receiving eslicarbazepine acetate (≥4% and ≥2% greater than placebo): dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor. ( 6.1 ) Adverse reactions in pediatric patients are similar to those seen in adult patients.

Source: FDA prescribing information (DailyMed). Set ID: 2067fb77-9657-44da-b430-02e8a4efacb5. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Eslicarbazepine (FDA label)

Eslicarbazepine acetate tablets are contraindicated in patients with a hypersensitivity to eslicarbazepine acetate or oxcarbazepine [see Warnings and Precautions (5.2 , 5.3 , and 5.4 )]. Hypersensitivity to eslicarbazepine acetate or oxcarbazepine. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 2067fb77-9657-44da-b430-02e8a4efacb5. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Eslicarbazepine (FDA label)

Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior. ( 5.1 ) Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established. ( 5.2 , 5.3 , 5.4 ) Hyponatremia: Monitor sodium levels in patients at risk or patients experiencing hyponatremia symptoms. ( 5.5 ) Neurological Adverse Reactions: Monitor for dizziness, disturbance in gait and coordination, somnolence, fatigue, cognitive dysfunction, and visual changes.

Source: FDA prescribing information (DailyMed). Set ID: 2067fb77-9657-44da-b430-02e8a4efacb5. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Eslicarbazepine (FDA label)

Carbamazepine: May need dose adjustment for eslicarbazepine acetate or carbamazepine. ( 2.3 , 5.6 , 7.1 ) Phenytoin: Higher dosage of eslicarbazepine acetate may be necessary and dose adjustment may be needed for phenytoin. ( 2.3 , 7.1 , 7.2 ) Phenobarbital or Primidone: Higher dosage of eslicarbazepine acetate may be necessary. ( 2.3 , 7.1 ) Hormonal Contraceptives: Eslicarbazepine acetate may decrease the effectiveness of hormonal contraceptives. ( 7.4 , 8.3 ) 7.1 Other Antiepileptic Drugs Several AEDs (e.g., carbamazepine, phenobarbital, phenytoin, and primidone) can induce enzymes that metabolize eslicarbazepine acetate and can cause decreased plasma concentrations of eslicarbazepine [see Clinical Pharmacology (12.3) ]. Higher doses of eslicarbazepine acetate may be needed [see Dosage and Administration (2.4) ] . 7.2 CYP2C19 Substrates Eslicarbazepine acetate can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole) [see Clinical Pharmacology

Source: FDA prescribing information (DailyMed). Set ID: 2067fb77-9657-44da-b430-02e8a4efacb5. Label effective date: August 7, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.